97. 潰瘍性大腸炎
[臨床試験数:2,269,薬物数:1,331(DrugBank:241),標的遺伝子数:114,標的パスウェイ数:181

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-000509-35-BG
(EUCTR)
27/10/201603/08/2016Drug OPRX-106 in Patients with Ulcerative ColitisAn Open Label, Proof of Concept Study to Assess the Safety, PK and Explore Efficacy of OPRX-106 in Patients with Active Mild to Moderate Ulcerative Colitis Active mild to moderate ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Product Name: OPRX-106 (plant cells expressing TNFR-Fc) 8mg
Product Code: OPRX-106
Product Name: OPRX-106 (plant cells expressing TNFR-Fc) 2mg
Product Code: OPRX-106
Protalix Biotherapeutics Ltd.NULLNot RecruitingFemale: yes
Male: yes
20Phase 2Serbia;Israel;Bulgaria
2NCT02768974
(ClinicalTrials.gov)
September 201627/3/2016Open Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative ColitisAn Open Label, Proof of Concept Study to Assess the Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative ColitisUlcerative ColitisDrug: OPRX-106ProtalixNULLRecruiting18 Years70 YearsBoth20Phase 2Israel